Almirall SA

Almirall’s CEO warns Europe’s pharma is fading, yet China’s approval of Seysara shows the company’s niche dermatology strengths—can it survive the decline?

Almirall SA, a Spanish pharmaceutical company, solidifies its position in the global market with a stable stock performance, robust financial standing, and a commitment to innovative treatments for dermatological and central nervous system condition…

Almirall SA reports strong Q1 2025 results, with 15% year-over-year sales growth and 35% increase in EBITDA, driven by success in European Dermatology and biologics portfolio.